Zheng Quan Zhi Xing·2025-08-22 12:20Group 1 - The core viewpoint of the article is that Yifang Biotechnology (Shanghai) Co., Ltd. plans to utilize part of its idle raised funds for cash management to enhance fund efficiency and returns for the company and its shareholders [1][2][5] Group 2 - The total amount of raised funds is RMB 208,380 million, with an issuance price of RMB 18.12 per share, approved by the China Securities Regulatory Commission on April 1, 2022 [1] - The company intends to use up to RMB 1 billion of temporarily idle raised funds for cash management, with a validity period of 12 months from the approval date by the board of directors [2] - The investment products will include low-risk, high-liquidity financial products such as structured deposits, time deposits, and large certificates of deposit, with a maximum investment period of 12 months [2] Group 3 - The decision to use idle funds for cash management was approved in the fifth meeting of the second board of directors on August 21, 2025, ensuring that it will not affect the normal operation of the company's main business or the progress of investment projects [2][4] - The company has established a robust approval and execution process for purchasing cash management products to ensure fund safety, including the use of dedicated settlement accounts [3][4] Group 4 - The sponsor, CITIC Securities, has verified that the company has followed necessary decision-making procedures and complies with relevant laws and regulations regarding the use of idle raised funds for cash management [5][6]